Management of bronchopulmonary dysplasia in infants: Guidelines for corticosteroid use

Drugs

Volumn 65, Issue 1, 2005, Pages 15-29

  Grier, David G ^a,b   Halliday, Henry L ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL MATERNITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BECLOMETASONE; BETAMETHASONE; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; CORTISONE; DEXAMETHASONE; ERYTHROMYCIN; FLUNISOLIDE; FLUTICASONE PROPIONATE; FUROSEMIDE; HYDROCORTISONE; INDOMETACIN; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RETINOL; SALBUTAMOL; SPIRONOLACTONE;

ACIDOSIS; BACTEREMIA; BODY WEIGHT DISORDER; BRAIN HEMORRHAGE; CEREBRAL PALSY; CHILD; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DEATH; DIGESTIVE SYSTEM PERFORATION; DISEASE EXACERBATION; DRUG MECHANISM; ENCEPHALOMALACIA; EXTUBATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; HYPOCAPNIA; HYPOTENSION; INFANT; INFECTION; INTESTINE PERFORATION; LOW DRUG DOSE; LUNG DYSPLASIA; LUNG FUNCTION; META ANALYSIS; MORBIDITY; MORTALITY; MOUSE; NECROTIZING ENTEROCOLITIS; NEUROTOXICITY; NEWBORN; NONHUMAN; PERINATAL DRUG EXPOSURE; PERINATAL PERIOD; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PREMATURITY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEPSIS; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; VENTILATOR;

ADRENAL CORTEX HORMONES; BRONCHOPULMONARY DYSPLASIA; DISEASE MANAGEMENT; HUMANS; INFANT, NEWBORN; PRACTICE GUIDELINES;

EID: 12444274924     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565010-00002     Document Type: Review

References (89)

1. Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996: NICHD Neonatal Research Network. Pediatrics 2001 Jan; 107 (1): E1-8
2. Sweet DG, Halliday HL. A risk-benefit assessment of drugs used for neonatal chronic lung disease. Drug Saf 2000 May; 22 (5): 389-404
3. Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study [electronic article]. Pediatrics 1998 May; 101 (5): E7
4. Horbar JD, Badger GJ, Carpenter JH, et al. Trends in mortality and morbidity for very low birth weight infants, 1991-1999. Pediatrics 2002 Jul; 110 (1 Pt 1): 143-51
5. Takeuchi T, Tanaka D, Saikawa N, et al. Changes of the physiological parameters of very low-birthweight infants with chronic lung disease treated with dexamethasone. Pediatr Int 2002 Apr; 44 (2): 122-6
6. Bancalari E, Abdenour GE, Feller R, et al. Bronchopulmonary dysplasia: clinical presentation. J Pediatr 1979 Nov; 95 (5 Pt 2): 819-23
7. Shennan AT, Dunn MS, Ohlsson A, et al. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988 Oct; 82 (4): 527-32
8. Bancalari E, Claure N, Sosenko IR. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neonatol 2003 Feb; 8 (1): 63-71
9. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001 Jun; 163 (7): 1723-9
10. Walsh MC, Wilson-Costello D, Zadell A, et al. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol 2003 Sep; 23 (6): 451-6
11. Northway Jr WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease: bronchopulmonary dysplasia. N Engl J Med 1967 Feb 16; 276 (7): 357-68
12. Van Lierde S, Cornells A, Devlieger H, et al. Different patterns of pulmonary sequelae after hyaline membrane disease: heterogeneity of bronchopulmonary dysplasia? A clinicopathologic study. Biol Neonate 1991; 60 (3-4): 152-62
13. Jobe A. The new BPD: an arrest of lung development. Pediatr Res 1999; 46: 641-3
14. Wilson MG, Mikity VG. A new form of respiratory disease in premature infants. Am J Dis Child 1960; 99: 489-99
15. Coalson JJ. Pathology of new bronchopulmonary dysplasia. Semin Neonatol 2003 Feb; 8 (1): 73-81
16. Parker RA, Lindstrom DP, Cotton RB. Improved survival accounts for most, but not all, of the increase in bronchopulmonary dysplasia. Pediatrics 1992 Nov; 90: 663-8
17. Naik AS, Kallapur SG, Bachurski CJ, et al. Effects of ventilation with different positive end-expiratory pressures on cytokine expression in the preterm lamb lung. Am J Respir Crit Care Med 2001 Aug 1; 164 (3): 494-8
18. Fardy CH, Silverman M. Antioxidants in neonatal lung disease. Arch Dis Child Fetal Neonatal Ed 1995 Sep; 73 (2): F112-7
19. Saugstad OD. Bronchopulmonary dysplasia-oxidative stress and antioxidants. Semin Neonatol 2003 Feb; 8 (1): 39-49
20. Asikainen TM, Raivio KO, Saksela M, et al. Expression and developmental profile of antioxidant enzymes in human lung and liver. Am J Respir Cell Mol Biol 1998 Dec; 19 (6): 942-9
21. Brown ER, Stark A, Sosenko I, et al. Bronchopulmonary dysplasia: possible relationship to pulmonary edema. J Pediatr 1978 Jun; 92 (6): 982-4
22. Koyama N, Ogawa Y, Kamiya K, et al. Increased platelet activating factor in the tracheal aspirates from neonates with patent ductus arteriosus. Clin Chim Acta 1993 Apr 16; 215 (1): 73-9
23. Saugstad OD, Buo L, Johansen HT, et al. Activation of the plasma kallikrein-kinin system in respiratory distress syndrome. Pediatr Res 1992 Oct; 32 (4): 431-5
24. Bland RD, Albertine KH, Carlton DP, et al. Chronic lung injury in preterm lambs: abnormalities of the pulmonary circulation and lung fluid balance. Pediatr Res 2000 Jul; 48 (1): 64-74
25. Jobe AH. Antenatal factors and the development of bronchopulmonary dysplasia. Semin Neonatol 2003 Feb; 8 (1): 9-17
26. Gonzalez A, Sosenko IR, Chandar J, et al. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 1996 Apr; 128 (4): 470-8
27. Watterberg KL, Gerdes JS, Cook KL. Impaired glucocorticoid synthesis in premature infants developing chronic lung disease. Pediatr Res 2001 Aug; 50 (2): 190-5
28. Watterberg KL, Gerdes JS, Gifford KL, et al. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999 Dec; 104 (6): 1258-63
29. Haddad HM, Hsia DY, Gellis SS. Studies on respiratory rate in the newborn; its use in the evaluation of respiratory distress in infants of diabetic mothers. Pediatrics 1956 Feb; 17 (2): 204-13
30. Baden M, Bauer CR, Colle E, et al. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 1972 Oct; 50 (4): 526-34
31. Ewerbeck H, Helwig H, Reynolds JW, et al. Treatment of idiopathic respiratory distress with large doses of corticoids. Pediatrics 1972 Mar; 49 (3): 467-8
32. Liggins GC. Premature parturition after infusion of corticotrophin or cortisol into foetal lambs. J Endocrinol 1968 Oct; 42 (2): 323-9
33. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972 Oct; 50 (4): 515-25
34. Taeusch Jr HW, Wang NS, Baden M, et al. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. II: pathology. Pediatrics 1973 Dec; 52 (6): 850-4
35. Fitzhardinge PM, Eisen A, Lejtenyi C, et al. Sequelae of early steroid administration to the newborn infant. Pediatrics 1974 Jun; 53 (6): 877-83
36. Mammel MC, Green TP, Johnson DE, et al. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983 Jun 18; I (8338): 1356-8
37. Avery GB, Fletcher AB, Kaplan M, et al. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics 1985 Jan; 75 (1): 106-11
38. Hack M, Fanaroff AA. Outcomes of children of extremely low birthweight and gestational age in the 1990's. Early Hum Dev 1999 Jan; 53 (3): 193-218
39. Tronche F, Kellendonk C, Reichardt HM, et al. Genetic dissection of glucocorticoid receptor function in mice. Curr Opin Genet Dev 1998 Oct; 8 (5): 532-8
40. Beato M, Truss M, Chavez S. Control of transcription by steroid hormones. Ann N Y Acad Sci 1996 Apr 30; 784: 93-123
41. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998 Jun; 94 (6): 557-72
42. Lipworth BJ. Therapeutic implications of non-genomic glucocorticoid activity. Lancet 2000 Jul 8; 356 (9224): 87-9
43. Losel R, Feuring M, Wehling M. Non-genomic aldosterone action: from the cell membrane to human physiology. J Steroid Biochem Mol Biol 2002 Dec; 83 (1-5): 167-71
44. Buttgereit F, Brand MD, Burmester GR. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol 1999 Jul 15; 58(2): 363-8
45. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; (1): CD001146
46. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; (1): CD001144
47. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; (1): CD001145
48. Halliday HL, Ehrenkranz RA. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 1999; (4): CD001146
49. Barrington KJ. Postnatal steroids and neurodevelopmental outcomes: a problem in the making. Pediatrics 2001 Jun; 107 (6): 1425-6
50. Barrington JK. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 1 2001: 1 [online]. Available from URL: http://www.biomedcentral.com/1471-2431/1/1 [Accessed 2004 Oct 13]
51. Papile LA, Tyson JE, Stoll BJ, et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med 1998 Apr 16; 338 (16): 1112-8
52. Halliday HL. Postnatal dexamethasone: what is the real cost-benefit ratio? Acta Paediatr 2003 Aug; 92 (8): 888-9
53. Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of chronic lung disease. Pediatrics. In Press
54. Ramanathan R, Siassi B, Sardesai S, et al. Comparison of two dosage regimens of dexamethasone for early treatment of chronic lung disease in very low birth weight (VLBW) infants: a double-blinded, randomised trial [abstract]. Pediatr Res 1996; 37: 229A
55. Durand M, Mendoza ME, Tantivit P, et al. A randomized trial of moderately early low-dose dexamethasone therapy in very low birth weight infants: dynamic pulmonary mechanics, oxygenation, and ventilation. Pediatrics 2002 Feb; 109 (2): 262-8
56. Stark AR, Carlo WA, Tyson JE, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants: National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001 Jan 11; 344 (2): 95-101
57. Bloomfield FH, Knight DB, Harding JE. Side effects of 2 different dexamethasone courses for preterm infants at risk of chronic lung disease: a randomized trial. J Pediatr 1998 Sep; 133 (3): 395-400
58. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 1989 Jun 8; 320 (23): 1505-10
59. Grier DG, Halliday HL. Corticosteroids in the prevention and management of bronchopulmonary dysplasia. Semin Neonatol 2003 Feb; 8 (1): 83-91
60. Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999 Oct 14; 341 (16): 1190-6
61. Baud O. Is perinatal dexamethasone treatment safe in preterm infants? Dev Med Child Neurol Suppl 2001 Mar; 86: 23-5
62. Baud O, Laudenbach V, Evrard P, et al. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res 2001 Dec; 50 (6): 706-11
63. Andre P, Thebaud B, Odievre MH, et al. Methylprednisolone, an alternative to dexamethasone in very premature infants at risk of chronic lung disease. Intensive Care Med 2000 Oct; 26 (10): 1496-500
64. van der Heide-Jalving M, Kamphuis PJ, van der Laan MJ, et al. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? Acta Paediatr 2003 Jul; 92 (7): 827-35
65. Watterberg KL. Prophylaxis of early adrenal insufficiency (AI) to prevent BPD: multicenter trial [abstract]. Pediatr Res 2004 Apr; 55 (4): 465A
66. Shah V, Ohlsson A, Halliday HL, et al. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2003; (4): CD001969
67. Lister P, Iles R, Shaw B, et al. Inhaled steroids for neonatal chronic lung disease. Cochrane Database Syst Rev 2003; (4): CD002311
68. Shah SS, Ohlsson A, Halliday HL, et al. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2003; (4): CD002058
69. Shah SS, Ohlsson A, Halliday HL, et al. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 2003; (4): CD002057
70. Halliday HL, Patterson CC, Halahakoon CW. A multicenter randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. Pediatrics 2001; 107: 232-4
71. Woodgate PG, Davies MW. Permissive hypercapnia for the prevention of morbidity and mortality in mechanically ventilated newborn infants. Cochrane Database Syst Rev 2003; (4): CD002061
72. Davis PG, Lemyre B, De Paoli AG. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev 2003; (4): CD003212
73. Davis PG, Henderson-Smart DJ. Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants. Cochrane Database Syst Rev 2003; (1): CD000143
74. Subramaniam P, Henderson-Smart DJ, Davis PG. Prophylactic nasal continuous positive airways pressure for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst Rev 2003; (4): CD001243
75. Henderson-Smart DJ, Bhuta T, Cools F, et al. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev 2003; (4): CD000104
76. Mabanta C, Pryhuber G, Weinberg G, et al. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev 2003; (4): CD003744
77. Brion LP, Primhak RA. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2003; (4): CD001453
78. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2003; (4): CD001817
79. Brion LP, Primhak RA, Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2003; (4): CD001694
80. Ng GY, da Silva O, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; (4): CD003214
81. Massaro GD, Massaro D. Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats. Am J Physiol 1996 Feb; 270 (2 Pt 1): L305-10
82. Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 2003; (4): CD000501
83. Brion L, Bell E, Raghuveer T. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2003; 4: CD003665
84. Suresh GK, Davis JM, Soll RF. Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. Cochrane Database Syst Rev 2001; 1: CD001968
85. American Academy of Pediatrics Committee on Fetus and Newborn, Canadian Paediatric Society Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002 Feb; 109 (2): 330-8
86. Halliday HL. Guidelines on neonatal steroids. Prenat Neonatal Med 2001; 6: 371-3
87. Truffert P, Empana JP, Breart G, et al. Treatment strategies for bronchopulmonary dysplasia with postnatal corticosteroids in Europe: the EURAIL survey. Acta Paediatr 2003 Aug; 92 (8): 948-51
88. Shinwell ES, Karplus M, Bader D, et al. Neonatologists are using much less dexamethasone. Arch Dis Child Fetal Neonatal Ed 2003; 88: F432-3
89. Halliday HL. Postnatal steroids: a dilemma for the neonatologist. Acta Paediatr 2001; 90: 116-8